APA (7th ed.) Citation

Nitta, K., Shi, S., Nagai, T., Kanasaki, M., Kitada, M., Srivastava, S. P., . . . Koya, D. (2016). Oral Administration of N-Acetyl-seryl-aspartyl-lysyl-proline Ameliorates Kidney Disease in Both Type 1 and Type 2 Diabetic Mice via a Therapeutic Regimen. BioMed Research International, 2016, 1. https://doi.org/10.1155/2016/9172157

Chicago Style (17th ed.) Citation

Nitta, Kyoko, Sen Shi, Takako Nagai, Megumi Kanasaki, Munehiro Kitada, Swayam Prakash Srivastava, Masakazu Haneda, Keizo Kanasaki, and Daisuke Koya. "Oral Administration of N-Acetyl-seryl-aspartyl-lysyl-proline Ameliorates Kidney Disease in Both Type 1 and Type 2 Diabetic Mice via a Therapeutic Regimen." BioMed Research International 2016 (2016): 1. https://doi.org/10.1155/2016/9172157.

MLA (9th ed.) Citation

Nitta, Kyoko, et al. "Oral Administration of N-Acetyl-seryl-aspartyl-lysyl-proline Ameliorates Kidney Disease in Both Type 1 and Type 2 Diabetic Mice via a Therapeutic Regimen." BioMed Research International, vol. 2016, 2016, p. 1, https://doi.org/10.1155/2016/9172157.